Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?
Peter Wind
Thu, August 20, 2026 at 2:36 AM GMT+5:30
5 min read
- LLY
-2.81%
Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historically associated with bariatric surgery and potentially giving Lilly another major product after the success of Mounjaro
The company’s stock price has benefited from this hype, gaining almost 9% in August. With Eli Lilly already valued at roughly $1.1 trillion and management recently raising its 2026 revenue guidance, investors are increasingly focused on whether future drug launches can support the premium valuation.
Here’s the latest Eli Lilly price prediction from CoinCodex analysts.
Retatrutide Could Become Eli Lilly’s Next Major Obesity Drug
Retatrutide is emerging as one of the most important products in Eli Lilly’s development pipeline. In the Phase 3 TRIUMPH-1 study, participants taking the drug lost an average of 28.3% of their body weight after 80 weeks.
Eli Lilly executive Patrik Jönsson described the results as being in a class of their own, saying the company had not previously seen weight reduction of that magnitude
The result is particularly significant when compared with existing obesity treatments. The report notes that patients taking Novo Nordisk’s Wegovy typically lose around 14% of their body weight after 72 weeks, while users of Lilly’s Mounjaro lose approximately 20% over a comparable period.
Retatrutide could therefore represent another substantial improvement in treatment effectiveness if the Phase 3 results translate into real-world use
Retatrutide could also broaden Lilly’s opportunity beyond weight reduction alone. The report highlights results from the TRIUMPH-4 study involving participants with knee osteoarthritis, where patients receiving retatrutide experienced a substantial reduction in pain.
That creates the possibility that the drug’s commercial value could eventually extend beyond the headline obesity numbers
Eli Lilly’s Obesity Business Is Already Producing Billions
The investment case does not depend solely on an experimental drug. Lilly has already demonstrated that highly effective metabolic treatments can translate into enormous commercial demand
Mounjaro generated more than €27 billion in revenue during the previous 12 months, according to the attached report.
Lilly’s success in obesity treatments has helped turn the Indianapolis-based company into the world’s most valuable pharmaceutical group, with its valuation around five times that of Novo Nordisk and more than four times that of AstraZeneca at the time of the report
